MPM BioVentures 2014, L.P. (EVNIN LUKE, GADICKE ANSBERT) sold $462K of TRDA (indirect holdings)
MPM BioVentures 2014, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock significantly.
Market read
Routine insider sale with limited trading relevance.
What to watch
Potential upcoming clinical data or financing events not disclosed.
Background
SEC Form 4 filings provide primary disclosure of insider transactions.
Ticker impact
Form 4 disclosed a $462K open‑market sale of 62,714 shares by insiders of Entrada Therapeutics.
Minor downward pressure, likely within normal volatility range.
Sale amount is small relative to market cap; no 10b5‑1 plan; typical insider diversification.
Market effects
Limited impact on biotech sector; reflects routine insider activity.
No regional effect.
Minimal global relevance.
Counterpoint
Insider sell could be unrelated to fundamentals; may not affect price.
Key entities
- CompanyEntrada Therapeutics, Inc.
Biotech firm (ticker TRDA) subject of insider sale.
